Windtree Therapeutics has not been shy about its desire to become a revenue-generating company, even when achieving that goal ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...

Hope is preparing for close-out meetings with the FDA. Chang said the team is “hopeful to advance to a phase 3 confirmatory trial” of the stem cell therapy candidate.

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to ...

BD has become the subject of a lawsuit from Tela Bio, with the rival maker of surgical mesh implants saying the major medtech wielded its sector dominance to push competing products out o | The rival ...